Source: International Congress 2018 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Falzon (Geneva, Switzerland), N. Ford (Geneva, Switzerland), E. Jaramillo (Geneva, Switzerland), P. Nahid (San Francisco, United States of America), P. Cegielski (Atlanta, United States of America), H. Schunemann (Hamilton, Canada), J. Brozek (Hamilton, Canada), K. Weyer (Geneva, Switzerland). Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance. 3686

Member's Comments

No comment yet.

Related content which might interest you: The new ATS/ERS/IDSA/CDC guidelines for MDR-TB: rationale, methods and recommendations Source: International Congress 2019 – Managing drug-resistant tuberculosis: from new guidelines to clinical practice Year: 2019 How do the new guidelines work? Practical approach to the new guidelines for asthma diagnosis in children, discussion and Q&A Source: Virtual Congress 2021 – The ERS guidelines for the diagnosis of asthma in children aged 5-16 years Year: 2021 WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion? Source: Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019 Year: 2020 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Tuberculosis: update on new diagnostic methods and treatment approach Source: Annual Congress 2007 - Infections year in review Year: 2007 What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis Source: Eur Respir Monogr 2018; 82: 414-429 Year: 2018 HAP/VAP : new guidelines, new approaches Source: International Congress 2018 – Chinese Programme 2018: Part II Year: 2018 How to apply evidence based practice critique method to review of guidelines Source: Annual Congress 2005 - Workshop: evidence-based practice: an approach to care Year: 2005 Emerging challenges to the development and implementation of clinical practice guidelines – COPD as a case in point Source: Annual Congress 2008 - Guideline development workshop summary: ATS/ERS integrating and coordinating efforts in COPD Year: 2008 Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019 Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation Source: Eur Respir J 2014; 44: 1412-1417 Year: 2014 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 Formulating recommendations and identifying areas of future research - Panel discussion and protocol Source: Research Seminar 2009 - The rationale and use of surfactant and continuous positive airway pressure (CPAP) in extremely low gestational age neonates (ELGANs) Year: 2009 Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Source: Eur Respir J 2009; 33: 871-881 Year: 2009 Rational monitoring of COPD: where do current clinical guidelines stand? Source: Eur Respir J 2007; 29: 1078-1081 Year: 2007 From patients to research laboratories and back: overview of the major scientific achievements and their impact in TB diagnosis, clinical management and control Source: Annual Congress 2013 –The best of TB PANNET Year: 2013 Clinical case discussion: How clinical trials inform antibiotic stewardship Source: ERS webinar 2022: Clinical case discussion: How clinical trials inform antibiotic stewardship Year: 2022 A clinical and aetiological evaluation of community acquired pneumonia-are we following guidelines in prescribing antibiotics? Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 New approaches for evaluation of treatment effectiveness among patients with pulmonary TB under DOTS implemented conditions Source: Eur Respir J 2002; 20: Suppl. 38, 368s Year: 2002